Navigation Links
CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
Date:11/9/2009

VIENNA, Va., Nov. 9 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM) announced today that Dr. Kenneth S. Rosenthal, Professor of Immunology and Microbiology of Northeastern Ohio Universities College of Medicine and Pharmacy, reported on work conducted in collaboration with scientists at the Cleveland Clinic and CEL-SCI on CEL-SCI's LEAPS vaccine technology. The data was presented at the 7th GTCbio Vaccine: "All Things Considered" Conference in Crystal City, Virginia.

Working with LEAPS vaccines for herpes simplex virus, HIV, rheumatoid arthritis and most recently, H1N1 influenza, the scientists' studies show that LEAPS peptide immunogens can convert precursor cells from mouse or humans to become dendritic cells (DC), the cell that directs the subsequent immune response. These DCs produce interleukin 12 (IL12p70), but without production of the pro-inflammatory cytokines that promote symptoms of a cytokine storm, such as tumor necrosis factor alpha or interleukin 1. Immunization with a LEAPS-immunogen for herpes simplex virus activates a protective T cell immune response against the virus in mice while a LEAPS-immunogen for treatment of rheumatoid arthritis (CEL-2000) reduces the production of the pro-inflammatory cytokines to block the progression of disease in mouse models of rheumatoid arthritis.

Dr. Rosenthal commented, "LEAPS immunogens are unique in their ability to simultaneously produce and activate a specific type of dendritic cell that can turn on or modulate antigen specific T cell responses without generating the pro-inflammatory cytokines associated with cytokine storm. The ability to activate the desired immune response should make LEAPS immunogens inherently safe vaccines. Finding of similar results for mouse and human cells in our laboratory studies adds confidence that the effects in the body will be the same in mice and man. "

Geert Kersten, CEO of CEL-SCI Corporation said: "We feel
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI Files Patent Application to Support Companys Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses
4. CEL-SCI Signs Definitive Agreement to Raise $5 Million in Registered Direct Offering
5. CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology
6. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
7. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
8. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
9. CEL-SCI Corporation Announces 2008 Financial Results
10. CEL-SCI Corporation Releases Letter to Shareholders
11. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... WA , Sept. 17, 2014 /PRNewswire/ - Oncothyreon ... it intends to offer and sell shares of its ... separate but concurrent underwritten public offerings.  The Series A ... of Oncothyreon Common Stock, provided that conversion will be ... affiliates would beneficially own more than 4.99% of the ...
(Date:9/17/2014)... A biodegradable polymer can be ... bacteria, fungi, and algae into smaller units (monomers) ... compounds, carbon dioxide, and humus in a specified ... improved costs, biodegradable polymers are proving to be ... conventional polymers. Primary factors that are responsible for ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... , Sept. 17, 2014 RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced that it has been granted ... Trademark Office on its unique delivery system for ... to phagocytic cells for the treatment of diseases ...
Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... CHICAGO, Sept. 28, 2011 GTL Resources PLC (AIM: GTL) ... on the state of its business. Julia Henderson, the non-executive ... trends and reaffirmed the current business approach: ... with expectations and in the six month period ending September ...
... Managing RA: The Strong Woman,s Approach ... women living with rheumatoid arthritis (RA), launched today at HealthyWomen.org. ... are two to three times more likely to develop the ... provides practical solutions and exercise advice specifically designed to ...
... delivery systems, solar cells, industrial catalysts and video displays ... possess two chemically distinct sides. These particles are named ... chemical faces allow them to form novel structures and ... of Janus particles down to a few nanometers in ...
Cached Biology Technology:The Strong Woman's Approach to Managing Rheumatoid Arthritis 2The Strong Woman's Approach to Managing Rheumatoid Arthritis 3The Strong Woman's Approach to Managing Rheumatoid Arthritis 4New technique maps twin faces of smallest Janus nanoparticles 2
(Date:9/17/2014)... from the Copenhagen Centre for Social Evolution and Yale ... that birth weight and -length can partially predict the ... as autism and schizophrenia later in life. The study ... subsequent hospital diagnoses for up to 30 years, and ... study is published today in the Proceedings of ...
(Date:9/17/2014)... 2014 Researchers at UTSouthwestern Medical Center have found ... apolipoprotein E, called apoE3, helps repair the lining of ... not get the benefit of this repair, putting them ... that we have identified one mechanism by which apoE3 ... variant, apoE4, is detrimental," said Dr. Philip Shaul ...
(Date:9/17/2014)... a great deal about complex social behavior by studying ... to teach too. , With their unusually large brains ... live in a complex social environment---not merely in a ... ants, but in a dynamic setting of alliances and ... mammals: dolphins, whales, primates, and social carnivores, like hyenas ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Being social: Learning from the behavior of birds 2
... over recent years have established a foothold in understanding ... it might contribute to aging and lifespan are not ... p53 function in fruit flies show new evidence that ... against tumor formation, normal levels of p53 activity--at least ...
... be published in the January 2006 issue of Nature ... Memorial Sloan-Kettering Cancer Center have devised a novel strategy ... to genetically reverse sickle cell disease (SCD) in human ... way to genetically correct this debilitating blood disease using ...
... years, biologists have searched for evolutionary clues to this ... play in the evolution of the postreproductive lifespan? ... years, postreproductive females should contribute to the fitness of ... effect." Though many mammals, including lions and baboons, rear ...
Cached Biology News:New clues to the dark side of a key anti-tumor guardian 2Sickle cell disease corrected in human models using stem cell-based gene therapy 2Getting an evolutionary handle on life after reproduction 2
... for biological safety labs (BSL) and ... Class 10/ISO 3) and easy sterilization. ... surfaces that are easy to wipe ... simplify cleaning. Unique double-wall panel design ...
... cleanroom for biological safety labs (BSL) ... (to Class 10/ISO 3) and easy ... ultra-smooth surfaces that are easy to ... corners simplify cleaning. Unique double-wall panel ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation of endotoxins for research purposes. sensitivity 0.05-0.1 EU/mL...
... testing at various temperatures, this chamber ... a clean heating unit to maintain ... 140F. Transparent panels allow full visibility, ... access to the work area. Includes ...
Biology Products: